PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 March; 7(1): E192–E198.
Published online 2006 March 24. doi:  10.1208/pt070127
PMCID: PMC2750734

Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene

Abstract

The purpose of this study was to improve the stability of cloricromene (AD6) in ophthalmic formulations and its drug availability at the ocular level. To this end, AD6-loaded polymeric nanoparticle suspensions were made using inert polymer resins (Eudragit RS100 and RL100). We modified the quasi-emulsion solvent diffusion technique by varying some formulation parameters (the drug-to-polymer ratio, the total drug and polymer amount, and the stirring speed). The chemical stability of AD6 in the nanosuspensions was assessed by preparing some formulations using (unbuffered) isotonic saline or a pH 7 phosphate buffer solution as the dispersing medium. The formulations were stored at 4°C, and the rate of degradation of AD6 was followed by high performance liquid chromatography (HPLC). The obtained nanosuspensions showed mean sizes and a positive surface charge (ζ-potential) that make them suitable for an ophthalmic application; these properties were maintained upon storage at 4°C for several months. In vitro dissolution tests confirmed a modified release of the drug from the polymer matrixes. Nanosuspensions prepared with saline solution and no or lower amounts of surfactant (Tween 80) showed an enhanced stability of the ester drug for several months, with respect to an AD6 aqueous solution. Based on the tecnological results, AD6-loaded Eudragit Retard nanoparticle suspensions appear to, offer promise as a means to improving the shelf life and bioavailability of this drug after ophthalmic application.

Keywords: Cloricromene, AD6, Eudragit Retard, nanosuspensions, quasi-emulsion solvent diffusion, nanoparticles, ophthalmic drug delivery, stability

Full Text

The Full Text of this article is available as a PDF (225K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Li VHK, Wood RW, Kreuter J, Harmia T, Robinson JR. Ocular drug delivery of progesterone using nanoparticles. J Microencapsul. 1986;3:213–218. doi: 10.3109/02652048609031575. [PubMed] [Cross Ref]
2. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly(ε-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res. 1993;10:386–390. doi: 10.1023/A:1018936205485. [PubMed] [Cross Ref]
3. Zimmer AK, Serbe H, Kreuter J. Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye, I: in vitro and in vivo characterization. J Control Release. 1994;32:57–70. doi: 10.1016/0168-3659(94)90225-9. [Cross Ref]
4. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41–50. doi: 10.1016/S0378-5173(97)00083-5. [Cross Ref]
5. Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by a Eudragit RS100® nanoparticle suspension. Ophthalmic Res. 2002;34:319–323. doi: 10.1159/000065608. [PubMed] [Cross Ref]
6. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247–3255. doi: 10.1016/S0142-9612(02)00080-7. [PubMed] [Cross Ref]
7. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;16:53–61. doi: 10.1016/S0928-0987(02)00057-X. [PubMed] [Cross Ref]
8. Kawashima Y, Iwamoto T, Niwa T, Takeuchi H, Hino T. Size control of ibuprofen microspheres with an acrylic polymer by changing the pH in an aqueous dispersion medium and its mechanism. Chem Pharm Bull (Tokyo) 1993;41:191–195.
9. Perumal D, Dangor CM, Alcock RS, Hurbans N, Moopanar KR. Effect of formulation variables on in vitro drug release and micromeritic properties of modified release ibuprofen microspheres. J Microencapsul. 1999;16:475–487. doi: 10.1080/026520499288924. [PubMed] [Cross Ref]
10. Pignatello R, Amico D, Chiechio S, Giunchedi P, Spadaro C, Puglisi G. Preparation and analgesic activity of Eudragit RS100 microparticles containing diflunisal. Drug Deliv. 2001;8:35–45. doi: 10.1080/107175401300002748. [PubMed] [Cross Ref]
11. Squadrito F, Prosdocimi M, Altavilla D, Zingarelli B, Caputi A. Cloricromene. Cardiovasc Drug Rev. 1991;4:357–371. doi: 10.1111/j.1527-3466.1991.tb00421.x. [Cross Ref]
12. Galli C, Agradi E, Petroni A, Socini A. Effects of 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy carboxyl methoxy coumarin (AD6) on aggregation, arachidonic acid metabolism and thromboxane B2 formation in human platelets. Pharmacol Res Commun. 1980;12:329–337. doi: 10.1016/S0031-6989(80)80089-0. [PubMed] [Cross Ref]
13. Porcellati S, Costantini V, Prosdocimi M, et al. The coumarin derivative AD6 inhibits the release of arachidonic acid by interfering phospholipase A2 activity in human platelets stimulated with thrombin. Agents Actions. 1990;29:364–373. doi: 10.1007/BF01966469. [PubMed] [Cross Ref]
14. Travagli RA, Zatta A, Banzatto N, et al. Molecular aspects of cloricromene (AD6) distribution in human platelets and its pharmacological effects. Thromb Res. 1989;54:327–338. doi: 10.1016/0049-3848(89)90091-1. [PubMed] [Cross Ref]
15. Bucolo C, Cuzzocrea S, Mazzon E, Caputi AP. Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci. 2003;44:1178–1184. doi: 10.1167/iovs.02-0559. [PubMed] [Cross Ref]
16. Kawashima Y, Niwa T, Handa T, Takeuchi H, Iwamoto T, Itoh K. Preparation of controlled-release micro spheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J Pharm Sci. 1989;78:68–72. doi: 10.1002/jps.2600780118. [PubMed] [Cross Ref]
17. Maltese A, Bucolo C. Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767:153–158. doi: 10.1016/S1570-0232(01)00567-0. [PubMed] [Cross Ref]
18. Benita S. Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Biomed Pharmacother. 1999;53:193–206. doi: 10.1016/S0753-3322(99)80088-2. [PubMed] [Cross Ref]
19. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol. 2000;5:521–532. doi: 10.1081/PDT-100102035. [PubMed] [Cross Ref]
20. Bucolo C, Maltese A, Maugeri F, Busà B, Puglisi G, Pignatello R. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol. 2004;56:841–846. doi: 10.1211/0022357023835. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists